AbbVie (ABBV) announced that a new 6-month 45mg LUPRON DEPOT, or leuprolide acetate for extended-release injectable suspension, strength has received Health Canada approval for the treatment of advanced prostate cancer. LUPRON DEPOT is now available in four dosing options.
LUPRON DEPOT is a hormonal medication approved by Health Canada for various conditions including advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. It is a synthetic gonadotropin-releasing hormone analog. LUPRON DEPOT was initially approved by Health Canada for advanced prostate cancer in 1989.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.